CN1289520C - 具有抗流感病毒的含CpG单链脱氧寡核苷酸 - Google Patents
具有抗流感病毒的含CpG单链脱氧寡核苷酸 Download PDFInfo
- Publication number
- CN1289520C CN1289520C CN 03146157 CN03146157A CN1289520C CN 1289520 C CN1289520 C CN 1289520C CN 03146157 CN03146157 CN 03146157 CN 03146157 A CN03146157 A CN 03146157A CN 1289520 C CN1289520 C CN 1289520C
- Authority
- CN
- China
- Prior art keywords
- oligonucleotide
- cpg
- deoxy
- synthetic
- influenza virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 18
- 241000700605 Viruses Species 0.000 title description 12
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims description 6
- 238000004073 vulcanization Methods 0.000 claims description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 7
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 43
- 238000000034 method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 239000005289 controlled pore glass Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- -1 phosphoramidite triester Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000003501 vero cell Anatomy 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 241000405217 Viola <butterfly> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 4
- 235000001892 vitamin D2 Nutrition 0.000 description 4
- 239000011653 vitamin D2 Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- GCHCDBOIRFPABI-UHFFFAOYSA-N NP(O)O.C1=NN=NN1.C1=NN=NN1 Chemical compound NP(O)O.C1=NN=NN1.C1=NN=NN1 GCHCDBOIRFPABI-UHFFFAOYSA-N 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000001459 mortal effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (4)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03146157 CN1289520C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
CNB2006101408530A CN100486588C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
EP04762006A EP1650218B1 (en) | 2003-07-25 | 2004-07-26 | The artificial cpg single strand deoxidation oligonucleotide and its antiviral uses |
CA2533434A CA2533434C (en) | 2003-07-25 | 2004-07-26 | Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
PCT/CN2004/000863 WO2005014611A1 (fr) | 2003-07-25 | 2004-07-26 | Oligodesoxyribonucleotide a simple brin cpg artificiel et utilisations antivirales |
DE602004031946T DE602004031946D1 (de) | 2003-07-25 | 2004-07-26 | Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen |
JP2006521375A JP4809220B2 (ja) | 2003-07-25 | 2004-07-26 | 人工合成CpG単鎖デオキシオリゴヌクレオチド及びその抗ウイルス作用 |
AT10174994T ATE532792T1 (de) | 2003-07-25 | 2004-07-26 | Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen |
AT04762006T ATE502949T1 (de) | 2003-07-25 | 2004-07-26 | Das künstliche cpg single strand deoxidation- oligonukleotid und dessen antivirale anwendungen |
US10/565,718 US7491706B2 (en) | 2003-07-25 | 2004-07-26 | Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
EP10174994A EP2264046B1 (en) | 2003-07-25 | 2004-07-26 | Artificial CpG single-stranded oligodeoxynucleotide and antiviral use thereof |
KR1020067001765A KR101146203B1 (ko) | 2003-07-25 | 2004-07-26 | 인공합성한 CpG 단일가닥 올리고데옥시뉴클레오티드 및이의 항바이러스 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03146157 CN1289520C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101408530A Division CN100486588C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569881A CN1569881A (zh) | 2005-01-26 |
CN1289520C true CN1289520C (zh) | 2006-12-13 |
Family
ID=34471626
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03146157 Expired - Lifetime CN1289520C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
CNB2006101408530A Expired - Lifetime CN100486588C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006101408530A Expired - Lifetime CN100486588C (zh) | 2003-07-25 | 2003-07-25 | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN1289520C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1304412C (zh) * | 2003-09-05 | 2007-03-14 | 长春华普生物技术有限公司 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
-
2003
- 2003-07-25 CN CN 03146157 patent/CN1289520C/zh not_active Expired - Lifetime
- 2003-07-25 CN CNB2006101408530A patent/CN100486588C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN101023957A (zh) | 2007-08-29 |
CN1569881A (zh) | 2005-01-26 |
CN100486588C (zh) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7308562B2 (ja) | 免疫増強用マンガン組成物 | |
CN1997391A (zh) | 以聚肌苷酸-聚胞苷酸为主的佐剂 | |
CN1608133A (zh) | 双链核糖核酸用于治疗正(+)链rna病毒感染的用途 | |
CN1050995C (zh) | 通过***的dsRNA治疗使宿主防御介质进入生物液体中 | |
CN103405762A (zh) | 以聚肌苷酸-聚胞苷酸为主的佐剂 | |
CN105664152A (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸复合物及其制备使用方法 | |
CN1289520C (zh) | 具有抗流感病毒的含CpG单链脱氧寡核苷酸 | |
CN1847256B (zh) | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 | |
CN1304412C (zh) | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 | |
KR101146203B1 (ko) | 인공합성한 CpG 단일가닥 올리고데옥시뉴클레오티드 및이의 항바이러스 용도 | |
CN114377127B (zh) | 一种三联卵黄抗体制剂及其制备方法和应用 | |
CN1498895A (zh) | 人工合成的含CpG单链脱氧寡核苷酸及其抗SARS病毒作用 | |
CN1687033A (zh) | 一种抗呼吸道病毒的药物及用途 | |
CN101029313A (zh) | 抗呼吸道合胞病毒的脱氧核酶及其在药中的应用 | |
CN111154755B (zh) | 一种双链寡核苷酸dna及其应用 | |
CN101073569A (zh) | 一种抗呼吸道病毒的药物及用途 | |
CN1293919C (zh) | 一种短棒状杆菌制剂或无细胞短棒状杆菌制剂在制备治疗hiv感染或爱滋病药剂中的应用 | |
CN105420243A (zh) | 人工合成的水貂特异性的CpG ODN及其应用 | |
Jain et al. | Antiviral Therapeutics | |
CN1138323A (zh) | 含聚硫脲的药物制剂及其使用方法 | |
CN1030140A (zh) | 用作病毒感染标记活化核糖核酸酶l | |
CN1513548A (zh) | 重组人干扰素α-2b口腔粘贴片及其制法 | |
CN1628846A (zh) | 用病毒类疫苗治疗病毒性疾病 | |
CN101041680A (zh) | 核酸分子rtn4bsr6及其在制备抗癌药物中的应用 | |
CN1422888A (zh) | 一种核酸类复合物及其生产方法和其在制备免疫制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Shao Yan Document name: Notice of application for publication of patent for invention and entry into the substantive examination procedure |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: High tech Zone of Jilin province Changchun Chaoqun street 130103 No. 191 incubator building block A room 306 Patentee after: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. Address before: 130021 Xinmin Street, Jilin, Changchun, China 4-28/1102-54 Patentee before: Changchun Huapu Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190415 Address after: Room 826-3, Block A, Phase I, Zhongdan Eco-life Science Industrial Park, 3-1 Xinjinhu Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Patentee after: Nanjing Freire Biotechnology Co.,Ltd. Address before: 130103 Room 306, Block A, Incubation Building, 191 Chaoqun Street, Changchun High-tech Zone, Jilin Province Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220128 Address after: 225300 vaccine Engineering Center building, Taizhou medical city, Jiangsu Province b517 Patentee after: Jiangsu taipurui Biotechnology Co.,Ltd. Address before: Room 826-3, Block A, Phase I, Zhongdan Eco-life Science Industrial Park, 3-1 Xinjinhu Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Patentee before: Nanjing Freire Biotechnology Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Shao Yan Document name: Notification of qualified procedures |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20061213 |